TANAKA Junji    Department   Other, Other    Position
Article types	Original article
Language	English
Peer review	Peer reviewed
Title	Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse.
Journal	Formal name：International journal of clinical oncology Abbreviation：Int J Clin Oncol ISSN code：14377772/13419625
Domestic / Foregin	Foregin
Volume, Issue, Page	26(11),pp.2142-2150
Author and coauthor	Yasui Hiroshi†, Kobayashi Masayuki, Sato Kota, Kondoh Kanya, Ishida Tadao, Kaito Yuta, Tamura Hideto, Handa Hiroshi, Tsukune Yutaka, Sasaki Makoto, Komatsu Norio, Tanaka Norina, Tanaka Junji, Kizaki Masahiro, Kawamata Toyotaka, Makiyama Junya, Yokoyama Kazuaki, Imoto Seiya, Tojo Arinobu, Imai Yoichi
Publication date	2021/11
Summary	BACKGROUND:Multiple myeloma (MM) is an incurable hematological malignancy. Despite the introduction of several novel drugs, most patients relapse. Biomarkers to identify the early signs of relapse will make it possible to adjust the therapeutic strategy before the disease worsens. Although understanding genetic changes is important for the treatment of MM, currently known biomarkers of relapse, including serum free-light chains and monoclonal paraproteins, are not associated with genetic changes.METHODS:We therefore performed a multicenter study to examine the usefulness of circulating cell-free DNA (cfDNA) present in the peripheral blood (PB) plasma of patients as a biomarker for MM relapse.RESULTS:We identified several driver mutations by combined analysis of next-generation sequencing and existing databases of candidate oncogenes. Furthermore, relapse was detected more sensitively by monitoring the circulating cfDNA with these driver mutations than by conventional serum free-light chain examination.CONCLUSION:These results suggest the potential utility of cfDNA in the PB plasma of patients as a relevant early biomarker for MM relapse.
DOI	10.1007/s10147-021-01991-z
PMID	34259983